Incyte (NASDAQ:INCY) resumed with Equal Weight rating and $87 (12% upside) price target at Morgan Stanley. Upgraded to Outperform with a $100 price target at Oppenheimer.
Alkermes plc (NASDAQ:ALKS) upgraded to Equal Weight with a $20 (flat) at Morgan Stanley.
Phibro Animal Health (NASDAQ:PAHC) upgraded to Equal Weight with a $21 (3% upside) price target at Morgan Stanley.
Sanofi (NASDAQ:SNY) upgraded to Outperform with a €100 (23% upside) price target at MainFirst.
Mallinckrodt (NYSE:MNK) downgraded to Market Perform with a $3 (16% upside) price target at BMO.
KemPharm (NASDAQ:KMPH) downgraded to Neutral at Roth Capital.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.